The GLP is committed to full transparency. Download and review our 2019 Annual Report

Does whole genome sequencing circumvent gene patents?

| | December 11, 2012
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

 What happens when, during the course of whole-genome sequencing (WGS) a patient or research subject, an investigator sequences and analyzes a disease gene that has been patented? The U.S. Supreme Court will shed some light on this question next year when it issues its ruling in the long-running Myriad Genetics saga. 

View the original article here: Does Whole Genome Sequencing Circumvent Gene Patents?

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend